Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates

HIV-1 gp41 is an envelope protein that plays an essential role in virus entry. The mutation of gp41 affects HIV-1 entry and susceptibility to the fusion inhibitor T-20. Therefore, we analyzed the natural polymorphism of gp41 of 163 HIV-1 isolates from T-20-naïve Koreans infected with HIV-1. This study of gp41 polymorphisms showed that insertions in the fourth threonine (74.8%) and L7M substitutions (85.3%) were more frequent in the fusion peptide motif in Korean HIV-1 isolates compared with those from other countries. Minor T-20 resistance mutations such as L45M (1.2%), N126K (1.2%), and E137K (6.7%) were detected, but the critical T-20 resistance mutations were not detected in the gp41 HR1 and HR2 regions. In addition, the N42S mutation (12.9%) associated with T-20 hypersusceptibility was detected at a high frequency. These results may serve as useful data for studies considering T-20 for use in the development of a more effective anti-retroviral treatment in Korea. Graphical Abstract

[1]  S. Sarafianos,et al.  Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. , 2013, The international journal of biochemistry & cell biology.

[2]  R. Shafer,et al.  Update of the drug resistance mutations in HIV-1: March 2013. , 2013, Topics in antiviral medicine.

[3]  Sung Soon Kim,et al.  Ten-year trends in HIV prevalence among visitors to public health centers under the National HIV Surveillance System in Korea, 2000 to 2009 , 2012, BMC Public Health.

[4]  Sung Soon Kim,et al.  Estimating the origin and evolution characteristics for Korean HIV type 1 subtype B using Bayesian phylogenetic analysis. , 2012, AIDS research and human retroviruses.

[5]  J.-y. Choi,et al.  Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  A. Tanuri,et al.  Genotypic Analysis of the gp41 HR1 Region From HIV-1 isolates From Enfuvirtide-Treated and Untreated Patients , 2011, Journal of acquired immune deficiency syndromes.

[7]  R. Diaz,et al.  Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy. , 2010, AIDS research and human retroviruses.

[8]  M. Chesney,et al.  Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors. , 2009, AIDS research and human retroviruses.

[9]  H. Jessen,et al.  Erratum to: Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon®) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy , 2007, Virus Genes.

[10]  M. Pietri,et al.  A cohort study of enfuvirtide immunological and virological efficacy in clinical practice , 2006, Journal of medical virology.

[11]  Stefano Bonora,et al.  Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. , 2006, The Journal of antimicrobial chemotherapy.

[12]  Deenan Pillay,et al.  Update of the drug resistance mutations in HIV-1: Fall 2006. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[13]  J. Erickson,et al.  Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro , 2005, Journal of Virology.

[14]  C. Hoffmann,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides , 2005, Journal of Virology.

[15]  L. Pérez-Alvárez,et al.  Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  D. Pillay,et al.  Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41 , 2005, Antimicrobial Agents and Chemotherapy.

[17]  M. Greenberg,et al.  Resistance to enfuvirtide, the first HIV fusion inhibitor. , 2004, The Journal of antimicrobial chemotherapy.

[18]  J. Kilby,et al.  Novel therapies based on mechanisms of HIV-1 cell entry. , 2003, The New England journal of medicine.

[19]  R. Doms,et al.  Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes. , 1999, Biochemistry.

[20]  M. Gottlieb,et al.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. , 1981, The New England journal of medicine.

[21]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[22]  H. Jessen,et al.  Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon®) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy , 2007, Virus Genes.